Lykan BioScience is an innovative contract development and manufacturing services organization (CDMO) focusing on cell-based therapies. Pioneering advancement in cell-based therapy development and manufacturing services, the company was founded in 2019 and operates in the Biotechnology and Manufacturing industries. In a Private Equity Round investment at 04 August 2022, the company secured funding from Pleasant Bay Capital Partners, GHO Capital, and WindRose Health Investors. This strategic investment signifies support and confidence from established industry players, positioning Lykan BioScience for further growth and advancements in the field of cell-based therapies.
No recent news or press coverage available for Lykan BioScience.